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Dehydroepiandrosterone (DHEA) is synthesized from cholesterol by activity of P450scc
and P450c17, enzymes that we previously characterized in the developing nervous sys-
tem.We describe the localization of P450c17 in the differentiated ﬁeld of the ventral spinal
cord in different motor neuron subtypes. We show that, during organogenesis, P450c17
activity is regulated along the antero/posterior axis of the spinal cord concomitantly with
the gradient of neurogenesis. To examine whether DHEA may modulate this process,
we measured proliferation and differentiation of ventral neural precursors in primary and
explant cultures. Our results showed that DHEA-induced the expression of class II pro-
tein Nkx6.1, motor neuron precursor Olig-2, and deﬁnitive motor neuron marker Isl-1/2.
DHEA also promoted proliferation of ventrally committed precursors in isolated spinal cord
precursor cultures and in whole spinal cord explants. Both the proliferative and inductive
effects of DHEA were dependent on sonic hedgehog signaling. The possibilities that the
effects observed with DHEA were due to its metabolism into androgens or to activation
of NMDA receptors were excluded. These results support the hypothesis that the tight
regulation of DHEA biosynthesis may be a biologic clock restricting the period of ventral
neuronal-precursor proliferation, thus controlling the number of pre-committed neurons in
the developing neural tube.
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INTRODUCTION
The topography of the central nervous system (CNS) results
from an orchestrated control of cell proliferation and motility,
maturation of neuronal and glial cells, axonal growth, and the
establishment of proper synapses. Neural speciﬁcation and pat-
terning of the CNS are controlled by the combinatory expression
of genes in the neural tube during development, establishing a
code for neuronal identity in restricted speciﬁc regions (Ruben-
stein and Beachy, 1998). Sonic hedgehog (Shh) is one of the major
morphogens controlling the expression of these homeodomain
proteins and plays a primordial role in dictating cell fate in neural
tube precursors through a graded signaling activity along the
ventro-dorsal axis (Briscoe et al., 2000; Jessell, 2000; Lee and Pfaff,
2001).
Patterning activity is not the only function of Shh. Mitogenic
activity of Shh has been observed in several tissues and organisms
during their development (reviewed in Ingham and McMahon,
2001; Brito et al., 2002; Marti and Bovolenta, 2002). In addition,
genetic alterations of Shh biogenesis or signal transduction lead to
CNS hyperplasia (reviewed in Litingtung and Chiang, 2000; Ruiz
i Altaba et al., 2002; Wetmore, 2003). In the neural tube, prolifer-
ative effects of Shh have been demonstrated in vitro and in vivo
(Kalyani et al., 1998;Rowitch et al., 1999).However, environmental
cues regulate the ability of precursor cells to proliferate in response
to Shh (Rowitch et al., 1999; Barzi et al., 2010). We proposed that
the neurosteroid dehydroepiandrosterone (DHEA) might be one
such cue controlling the proliferative response of precursors to
Shh.
DHEA is a secreted neurosteroid biosynthesized de novo in the
developing CNS from the sequential action of two cytochrome
P450 enzymes, P450scc and P450c17 (Compagnone and Mellon,
2000). To determine whether DHEA is produced in the regions
where we have found P450c17 expressed and what its bioactivity
may be, we focused our study on the developing spinal cord where
P450c17 expression is ﬁrst observed.
In this report, we establish a correlation between the expres-
sion and activity of P450c17 and show that P450c17 activity,
and thus most likely DHEA biosynthesis, are regulated along the
antero/posterior (A/P) axis of the developing spinal cord con-
comitantly with the gradient of neurogenesis. DHEA mimicked
Shh signaling to promote the induction of motor neurons and
sustained ventral progenitor proliferation in a Shh-dependent
manner in vitro. The results of this work support the hypothesis
that the tightly regulated biosynthesis of DHEA may be a biologic
clock restricting the period of ventral neuronal-precursor prolifer-
ation and thus controlling the number of pre-committed neurons
in the developing neural tube.
MATERIALS AND METHODS
All experiments were reviewed and approved by the Institutional
Animal Care and Use Committee at the University of California,
San Francisco, CA, USA.
REAGENTS AND CHEMICALS
DHEA, BrdU, poly-d-lysine, progesterone, and streptavidin–
FITC were purchased from Sigma/RBI (St. Louis, MO, USA);
www.frontiersin.org February 2012 | Volume 3 | Article 16 | 1
Galdo et al. DHEA and ventral spinal cord precursors
CollagenaseH, insulin–transferrin–sodium selenium supplement,
and the terminal deoxynucleotidyl transferase biotin d-UTP nick-
end labeling (TUNEL) “In situ Cell Death Detection Kit,” Fluores-
cein from Roche Diagnostics (Indianapolis, IN, USA); and bFGF,
Leibovitz’s L15 medium, high-glucose formula of DMEM, and
HAM-F12 medium from Invitrogen/Gibco (Carlsbad, CA, USA).
[3H]pregnenolone was obtained from NEN/Perkin-Elmer Life
Sciences (Boston, MA, USA). The following antibodies were pur-
chased from the Developmental Studies Hybridoma Bank (DSHB,
University of Iowa, IA, USA): anti-Shh (5E1), Isl-1 (40.2D6),
Lim1/2 (4F2), and Pax6. The anti-Shh (5E1), anti-Isl-1 (40.2D6),
and anti-Lim1/2 (4F2) antibodies, developed by Dr. Thomas Jes-
sell, the anti-Pax6 and the anti-Pax7 antibodies, developed by Dr.
Atsushi Kawakami were fully characterized prior to their use in
this paper, Hoechst, Alexa 546-coupled goat anti-mouse, Alexa
350-coupled goat anti-rabbit, neutravidin–Alexa 350,wheat-germ
agglutinin, and the FluoroReporter Mini-biotin protein labeling
kitwere obtained fromMolecular probes (Eugene,OR,USA).Goat
anti-rabbit coupled to Phycoerythrin was bought from Chemi-
con (Temecula, CA, USA) and goat anti-mouse coupled to FITC
from Jackson ImmunoResearch Laboratories Inc., (West Grove,
PA, USA).
ANALYSIS OF ENZYMATIC ACTIVITY
Embryos were obtained from CD-1 mice (Charles River, Wilm-
ington, MA, USA) at different ages from embryonic day (E) 10
to E16.5 (E0.5= day of vaginal plug). Spinal cords were dissected
in L15 medium containing 5% heat-inactivated horse serum. The
spine was exposed after removal of the ventral organs. The noto-
chord was peeled off and collected. Mesenchyme surrounding the
spinal cord was carefully removed and collected, as were the dorsal
root ganglia (DRG). The spinal cords were opened dorsally, ﬂat-
tened, and then cut into dorsal (roof plate+ alar plate) and ventral
(ﬂoor plate+motor columns) segments.Dorsal and ventral halves
at all A/P levels were collected and analyzed separately. The geni-
tal ridges/gonads were collected as a positive control for P450c17
activity. Parts collected from three embryos were routinely pooled
for the analyses and yielded reproducible and signiﬁcant levels of
DHEA biosynthesis.
The segments analyzed were homogenized in 0.25M sucrose,
0.5mM EDTA, and 10mM Tris–Cl, pH 7.4, at 4˚C and incu-
bated with [3H]pregnenolone for 16 h at 37˚C. Tissues were then
extracted with isooctane:ethyl acetate (1:1, v:v) and dried under
N2 before analysis with thin-layer chromatography (TLC), using
a solvent mix of chloroform:ethyl acetate (1:3, v:v). Radiolabeled
steroids were identiﬁed by using steroid standards and a puriﬁed
preparation of P450c17-expressing yeast microsomes. Quantiﬁ-
cation of the percent conversion was obtained by using a Storm
phospho-imager (Molecular Dynamics, Amersham Biosciences,
Piscataway,NJ,USA) and Imagequant software.At least three inde-
pendent experiments were performed for each segment and for
each time point.
SPINAL CORD PRECURSORS: PRIMARY CULTURES
Dissections were performed in L15 medium. E10.5 CD-1 mouse
embryos were transected below the otic vesicle and in the center of
the hindlimb bud. The segment of the spinal cord used extended
from the center of the hindlimb bud to three somites rostrally,
and only the ventral and intermediate neural plates were retained.
Dissected segments were mechanically separated from the mes-
enchyme and dissociated with collagenase H (0.045U/ml). Iso-
lated cells were cultured on poly-d-lysine-coated glass coverslips
at 43,000 cells/cm2 in a serum-free medium (DMEM/F12) con-
taining 50 ng/ml basic ﬁbroblast growth factor (bFGF), 5μg/ml
insulin, 5μg/ml transferrin, 3× 10−8 M selenium, 2× 10−8 M
progesterone, and, when tested, DHEA at 10−10 M. When stated,
cells were grown in the presence of the 3μg/ml 5E1 anti-Shh
antibody raised against the N-terminal fragment of Shh.
After various times in culture, ranging from 3 to 45 h, BrdU
(10μM) was incorporated for 1 h and cells were washed in PBS
and ﬁxed with glycine:ethanol (3:7, v:v) for 45min at room tem-
perature. DNA was denatured by using 4M HCl for 10min. Cells
were washed and immunostained for BrdU (mouse anti-BrdU
antibody used at 1:50), for NeuN (biotinylated mouse anti-NeuN
antibody used at 1:200), for Isl-1 (rabbit anti-Isl-1/2 antibody, gift
from Dr. Pfaff, used at 1:2,000), for Nkx6.1 (rabbit anti-Nkx6.1,
gift from Dr. German, used at 1:4,000), and for Pax6 (DSHB,
used at 1:20). Secondary antibodies were a goat anti-mouse-Alexa
546, a streptavidin–FITC, and a goat anti-rabbit-Alexa 350, which
were used at 1:500, 1:200, and 1:500 respectively. TUNEL analy-
sis was performed by using the “In situ Cell Death Detection Kit”
as described previously (Hagedorn et al., 2000). Total cell number
was determined on each slide afterHoechst or ﬂuorescent-coupled
wheat-germ agglutinin counter-staining.
At least ﬁve independent experiments were performed for each
time point. Cells immunopositive for BrdU, NeuN, Isl-1, Nkx6.1,
Pax6, Chx10, Eng-1, or O4 were counted in 10 randomly selected
1mm2 ﬁelds/slide; three slides were counted per treatment and per
experiment. A general factorial multiple analysis of variance was
performed to determine the effects of the time in culture and of
the presence of DHEA in the culture medium, as well as a possible
interaction between these two factors.
HISTOCHEMISTRY
In situ hybridization and immunochemistry in mouse embryos
were performed as described previously (Compagnone et al.,
1995a).
DHEA-producing neurons were identiﬁed by using an anti-
P450c17 antibody (gift from Dr. Miller) used at 1:5,000. Motor
neurons were immunodetected with a mouse anti-Isl-1 antibody
at 1:50.Whendual or triple labelingwas performed,anti-Isl-1 anti-
body was biotinylated. Isl-1 immunoreactive neurons were then
revealed with neutravidin–Alexa 350 used at 1:1,000. V2 interneu-
rons were immunodetected by using an anti-Chx10 antibody (gift
from Dr. Pfaff) at 1:50. The pool of ventrally committed pre-
cursors was immunodetected with an anti-Nkx6.1 antibody (gift
fromDr. German) at 1:4,000, and the dorsally committed neurons
were immunodetectedwith an anti-Pax6 antibody (DSHB) used at
1:20. Pools of motor neurons were identiﬁed by using anti-Isl-1/2
(40.2D6, DSHB) at 1:100, anti-Isl2 (gift from Dr. Pfaff) at 1:2,000,
anti-Lim1/2 (4F2, DSHB) at 1:100, anti-Lim3 (gift fromDr. Pfaff)
at 1:3,000, and anti-HB9 (gift fromDr. Pfaff) at 1:8,000. Secondary
antibodies were an anti-rabbit-Phycoerythrin (Chemicon) and an
anti-mouse-FITC (Jackson ImmunoResearch), both used at 1:200.
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THREE-DIMENSIONAL SPINAL CORD EXPLANT CULTURES
Whole neural tube explants
The assay was performed as previously described (Colamarino
and Tessier-Lavigne, 1995). Spinal cords were removed from E11.5
mouse embryos in L15 medium and, after elimination of the mes-
enchyme, the mid-lumbar, and sacral segments were collected.
Explants were dissected out of the spinal cord, ﬂattened, and
then were cut to approximately 800μm in length. They were
placed in 0.04ml collagen beads made fresh from rat-tail ten-
dons, and cultures were carried out in the same medium as the
spinal cord precursor cultures.When speciﬁed, 10−10 M of DHEA
or 16-ﬂuoro-5-androsten-17-one (ﬂuasterone) and/or anti-Shh
antibody (3μg/ml) were added to the culture medium. After 21 h
of culture, BrdU incorporation (10μM) was carried out for a
pulse of 3 h to permit diffusion of the reagent through the colla-
gen gel. Explants were ﬁxed with 4% paraformaldehyde as stated
earlier. BrdU detection was performed as described earlier and
quantiﬁed. Results were obtained from at least four independent
experiments.
INTERMEDIATE NEURAL PLATE EXPLANTS: MOTOR NEURON
INDUCTION ASSAY
Intermediate neural plates were dissected out of E10mouse neural
tubes following a procedure adapted from that described for
the chick embryo (Roelink et al., 1995; Ericson et al., 1996;
Incardona et al., 1998). Isolated intermediate neural plates were
cut into 100μm pieces and cultures in collagen gel matrices
as described earlier. Explants were grown in DMEN-F12 1:1
medium containing 50 ng/ml FGF, 5μg/ml insulin, 5μg/ml trans-
ferrin, 3× 10−8 M selenium, and 2× 10−8 M progesterone for
12 h before receiving the N-terminal fragment of Shh (R&D
System Inc., Minneapolis, MN, USA) at 2–20 nM ±DHEA or
±DHEA, and speciﬁc inhibitors of Shh signaling (5E1 antibody
used 3μg/ml or 1.2μM cyclopamine (TRC Inc., Toronto, CA,
USA).After 24 h in the experimentalmedium,explantswere rinsed
in PBS and ﬁxed in 4% PFA for 24 h. Explants were processed
for immunocytochemical determination of the expression of class
II and class I homeodomain proteins (Nkx6.1 and Pax7, respec-
tively), Olig-2, and Isl-1/2. Results were obtained from at least
four independent experiments. A minimum of eight different
explants per experimental condition were quantiﬁed. The quan-
tiﬁcation of Nkx6.1, Pax7, Olig-2, and Isl-1/2 immunopositive
nuclei was performed using a computer assisted imaging software
(Slidebook from Intelligent Imaging Innovation,) specialized in
such morphometric analyses. This software allows the recogni-
tion of both in signal intensity and the shape (size) of the object
stained allowing for a reduction of the bias when assessing the
number of nuclei in ﬁeld containing a high density of stained
nuclei.
STATISTICAL ANALYSIS
Results are presented as means± SEM. MANOVA and ANOVA
algorithms were used to determine differences among groups
using SPSS software (SPSS Inc., Chicago, IL, USA) and Bonfer-
roni’s post hoc test (signiﬁcance established at 95%). Asterisks
indicate statistically signiﬁcance levels, ∗ = p< 0.05, ∗∗ = p< 0.01,
∗∗∗ = p< 0.001.
RESULTS
EXPRESSION OF P450c17 IN THE DEVELOPING MOTOR NEURONS
We previously identiﬁed the distribution of P450scc and P450c17,
enzymes crucial for the production of DHEA, in the developing
nervous system (Compagnone et al., 1995a,b). P450c17 expression
is regionally anddevelopmentally regulated in neurons of theCNS,
including those in the position of motor neurons in the spinal cord
(Compagnone et al., 1995a). We therefore asked if the expression
pattern of P450c17was temporally and regionally regulatedwithin
the different subtypes of neuronal populations in the developing
neural tube. P450c17 was expressed early in development in the
cervical neural tube (E9–E10) and later in the brachial/thoracic
(E10–E11) and in the lumbar (E12.5) segments (data not shown).
At E13.5, P450c17 was expressed at all levels of the developing
spinal cord, with the weakest signal seen at the brachial level
(Figure 1A). P450c17 was observed in both the ventral and dorsal
regions of the spinal cord. In the dorsal region, P450c17 antibody
labeled commissural neurons whose axons crossed the ﬂoor plate
ventrally (not shown). In the ventral spinal cord, P450c17 was
expressed in cell bodies and ﬁbers in a ventro-medio-lateral posi-
tion, suggesting that P450c17 could be localized either in precursor
cells migrating out of the sub ventricular zone (SVZ) or in cells
FIGURE 1 | P450c17 expression in the developing spinal cord in the
mouse. (A) Immunostaining of P450c17 in E13.5 sagittal sections of the
spinal cord. (B) Co-expression of P450c17 (green) with Isl-1, Isl2, Lim1/2,
Lim3, and HB9 (red) in an E13.5 transverse section of whole embryo
(thoracic level of the spinal cord). For each marker, an overlay with P450c17
is shown, as well as a high magniﬁcation view. P450c17 being a
microsomal protein, its staining is found both in cell bodies and in ﬁbers,
whereas Isl-1, Isl2, Lim1/2, Lim3, and HB9 are nuclear proteins. Asterisks
indicate cells dually labeled. (A–C) Bars equal 100μm. (D) Schematic
representation of the expression domains of P450c17 in the different
domains of motor neuron subtypes markers.
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that have already acquired a differentiated phenotype but are still
located close to the SVZ boundary. To determine the cellular local-
ization of P450c17 in the ventral spinal cord, we performed dual
immunostaining or dual immuno-hybrido-staining with Nkx2.2
and Nkx6.1, markers for ventrally committed precursors (Jessell,
2000; Lee and Pfaff, 2001). Although P450c17 and Nkx2.2 mRNA
were observed in the same regions in the E10.5 spinal cord, they
were not expressed in the same cells: Nkx2.2 mRNA was generally
expressed in cells clustered in amoremedial position than the cells
expressing P450c17 (data not shown). P450c17 co-localized with
Nkx6.1 only in cells migrating in the differentiated ﬁeld in E10.5
mouse embryos (data not shown), but its expression domain was
not restricted to Nkx6.1 immunopositive cells. P450c17 expres-
sion was also seen in cells in the differentiated ﬁeld in the position
of motor neurons. To identify the subpopulations of cells in which
P450c17 was expressed, we used Isl-1 as a marker for motor neu-
rons and Chx10 as a marker for V2 interneurons (Jessell, 2000;
Lee and Pfaff, 2001). In E13.5 mouse embryos, we found P450c17
localized in a subset of Isl-1+ motor neurons but not in Chx10+
interneurons (data not shown). In an attempt to further charac-
terize P450c17 expression in motor neuron pools, we used HB9 as
a marker of pre-mitotic motor neurons, Isl-1 as a marker of post-
mitotic motor neurons and Isl2, Lim1/2, and Lim3 as markers for
the different columnar identities (Jessell, 2000). At E13.5, P450c17
was expressed in motor neuron immunopositives for Isl-1 or HB9
pre-mitotic neurons (Figures 1B,C). It co-localizedwith subsets of
cells immunopositive for Isl2, Lim1/2, and Lim3 (Figures 1B,C).
Our results showed that P450c17 did not segregate with a particu-
lar population of motor neurons, but rather that it was expressed
by motor neurons in the ventro-medio-lateral region of the dif-
ferentiated ﬁeld (see Figure 1D). This ﬁnding suggests that DHEA
may be secreted by this population of neurons and thus may act
on neighboring cells.
P450c17 ACTIVITY IN THE DEVELOPING NEURAL TUBE
To establish a correlation between the protein expression and the
enzymatic activity of P450c17, we performed TLC analysis of
radiolabeled metabolites of [3H]pregnenolone, the substrate of
P450c17 (Figure 2A). Conversion of pregnenolone into DHEA
results from the sequential action of the two enzymatic activi-
ties of P450c17: 17α-hydroxylase and 17–20 lyase activities. Both
activities are represented in Figure 2 as a percent conversion of
pregnenolone into DHEA (Figures 2B,D) and into 17-OH preg-
nenolone (Figures 2C,D). As positive controls, we used gonadal
ridges of similar developmental stages (averaging a basal percent
conversion of pregnenolone into DHEA of 5%, not signiﬁcantly
modiﬁed during embryogenesis) and a preparation of yeast over-
expressing P450c17 (Auchus et al., 1998) or adult male testis
homogenates. To determine whether P450c17 activity was reg-
ulated in the D/V axis of the developing neural tube, we dissected
ventral and dorsal regions of the brachial/thoracic spinal cord
of mouse embryos at different embryonic ages and measured
P450c17 activities (Figures 2B,C). Similarly, to determine if DHEA
biosynthesis was regulated along the A/P axis, we dissected differ-
ent regions of the developing spinal cord at different A/P levels
(cervical, brachial, thoracic, and lumbar) in E10.5–E16.5 embryos
(Figure 2D).
Biosynthesis of DHEA was observed in both the ventral and
the dorsal regions of the spinal cord (Figure 2B), consistent with
P450c17 expression. No DHEA was produced in the mesenchyme
or in the notochord, where P450c17 is not expressed (Figure 2A,
lanes 11–12). No further conversion of DHEA into androgens was
observed in the embryonic nervous system tissue.
In the brachial–thoracic region of the spinal cord,no signiﬁcant
differences were observed between dorsal and ventral biosynthesis
of DHEA or 17-OH pregnenolone at the different embryonic ages
analyzed (Figures 2B,C). However, DHEA biosynthesis was regu-
lated along the A/P axis during the development of the spinal cord
(Figure 2D). A two-way analysis of variance showed a signiﬁcant
interaction between the segmental position of the sample analyzed
along the A/P axis and the embryonic age. We thus performed
one-way analysis on the percent conversion of pregnenolone into
DHEA for each of these factors and observed a signiﬁcant peak of
DHEA biosynthesis traveling along theA/P axis during embryoge-
nesis (Figure 2D, black line). This peakwas observed in the cervical
region of the spinal cord at E10.5 (the earliest time point analyzed),
in the brachial region at E11.5, in the thoracic part at E12, and in
the lumbar portion at E12.5. The peak of DHEA biosynthesis was
thus concomitant with the rostro-caudal gradient of neurogene-
sis described in the developing neural tube (Nornes and Carry,
1978). No signiﬁcant changes were observed in the percent con-
version of pregnenolone into 17-OH pregnenolone (Figure 2D,
gray line). The average peak value of DHEA biosynthesis is about
2.85% (±1.02%), a value comparable to those obtained from the
mouse adult testis, where DHEA serves as precursor for andro-
gens (not shown). These low conversion levels were close to the
sensitivity limit of the technique used but were readily quantiﬁable
and reproducible, andDHEA production was conﬁrmed byHPLC
(not shown).
These results show that P450c17 expressionwas associated with
P450c17 activity, and that DHEA was most likely produced in the
ventral and dorsal spinal cord at a time consistent with its poten-
tial role in the modulation of neurogenesis or differentiation of
neural precursors. DHEA is a lipophilic steroidal compound that
can cross the plasma membrane. It may therefore act from a dis-
tance on cells in the SVZ. For the rest of this report we focused our
investigations on the ventral regions of the neural tube in the aim
to determine the role of DHEA.
EFFECT OF DHEA PROLIFERATION AND NEURONAL DIFFERENTIATION
IN ISOLATED SPINAL CORD PRECURSOR CULTURES
DHEA affects proliferation of ventrally committed precursors and
differentiation of motor neurons in vitro
DHEA biosynthesis occurs in the developing spinal cord concomi-
tantly with the gradient of neurogenesis and neuronal differenti-
ation. DHEA may thus modulate proliferation or differentiation
of cells present in the region where it is secreted. To test this pos-
sibility we cultured spinal cord precursors isolated from E10.5
ventral neural tube in a serum-free medium in the presence or
in the absence of DHEA for 3–45 h. We studied the effect of
DHEA at a concentration of 10−10 M, which has proved to be
efﬁcient as previously determined on embryonic neocortical cul-
tures (Compagnone andMellon, 1998).Weﬁrst analyzed the effect
of DHEA on proliferation, using BrdU incorporation performed
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FIGURE 2 | Biosynthesis of steroid products derived from P450c17
activity in vivo in the developing spinal cord. (A)Typical TLC plate from
E12.5 embryos. 1: spinal cord (SpC) cervical ventral, 2: SpC cervical dorsal,
3: SpC brachial ventral, 4: SpC brachial dorsal, 5: SpC thoracic ventral, 6: SpC
thoracic dorsal, 7: SpC lumbar ventral, 8: SpC lumbar dorsal, 9: genital ridge,
10: DRG, 11: notochord, 12: mesenchyme, 13: brain. Preg, pregnenolone;
Prog, progesterone. Arrows point to DHEA and 17-OH pregnenolone. (B,C)
Biosynthesis of DHEA (B) and 17-OH pregnenolone (C) was determined in
the ventral (black line) and dorsal portion (gray line) of the brachial–thoracic
segment of the spinal cord sampled at E10.5, E11.5, E12, E12.5, and E14.5.
A general factorial analysis was performed to assess the signiﬁcance of the
position of the sample along the ventro-dorsal axis and the embryonic age
on either the percent conversion of pregnenolone into DHEA or 17-OH
pregnenolone. No difference was found. (D) Biosynthesis of DHEA (black
line) and 17-OH pregnenolone (gray line) was determined in the cervical,
brachial, thoracic, and lumbar segments of the spinal cord sampled at E10.5,
E11.5, E12, E12.5, E14.5, and E16.5. The results show the average percent
conversion of pregnenolone into DHEA and 17-OH pregnenolone of the
ventral and dorsal measurements that were pooled for subsequent analysis,
as no signiﬁcant differences were observed between these two groups. A
general factorial analysis showed a signiﬁcant interaction between the
segmental position along the A/P axis and the embryonic age only on DHEA
biosynthesis (p<0. 05) but not on 17-OH pregnenolone biosynthesis.
One-way ANOVA showed that the peak of DHEA biosynthesis traveling
along the A/P axis is signiﬁcant for at least one of the two factors studied
(either position along the A/P axis or embryonic age). Values represent the
means±SEM of 20 independent measures of samples from pools of three
embryos.
as a 1 h pulse before ﬁxation of the cells. DHEA signiﬁcantly inﬂu-
enced the dynamics of the culture and increased both the number
and the percent of cells proliferating over time when compared
to control conditions (p< 0.0001, MANOVA). To obtain greater
detail we compared the proliferation of cells cultured in the pres-
ence of DHEA to that of cells cultured in the absence of DHEA
at different time points (every 3–5 h from 3 to 35 h and every
10 h thereafter) by using one-way ANOVA. The number of BrdU-
incorporating cells increased in the presence of DHEA at nearly
all time points examined (Figure 3A). The percentage of cells
incorporating BrdU over the total cell number showed time peri-
ods during which proliferation was very signiﬁcantly increased in
the presence of DHEA (Figure 3B). Increased BrdU incorpora-
tion was particularly evident in DHEA-treated cultures after 7 h
(with 38.4%± 1.2 cells in S-phase), 18 h (with 48.3%± 1.4 cells
in S-phase), and 35 h (with 62.5%± 7.5 cells in S-phase) as com-
pared to a relatively stable 30% proliferation rate over time in the
control conditions (28.6%± 1.0, 33.5± 0.9, and 36.2± 2.7 cells
in S-phase respectively). This pattern of BrdU incorporation
was particularly intriguing and suggestive of active cycling in
the DHEA-treated cultures. Consistent with increased prolifer-
ation in the DHEA-treated culture, the number of cells/cm2
increased over time to a higher extent in DHEA-treated cul-
tures than in control cultures (Figure 3C). In the presence of
DHEA, the growth rate abruptly dropped after 40–45 h in cul-
ture, which was indicative of cell death not seen in the control
condition, where the growth curve had stabilized (Figure 3C).
We then analyzed apoptosis in the culture by using the TUNEL
assay. The apoptotic rate was indistinguishable between the two
culture conditions from 3 to 40 h in culture. After 40–45 h in cul-
ture, a larger number of cells died from apoptosis in the cultures
grown in the presence of DHEA. However, apoptosis did not fully
account for the total number of lost cells at that time, so other
cell death mechanisms may be involved. This result nonetheless
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FIGURE 3 | Effect of DHEA on proliferation of precursor cells isolated
from E10.5 mouse neural tube lumbar region in primary culture. (A)
Number of immunopositive cells for BrdU. Cells were incubated for different
period of time in the absence (control, gray line) or presence of 10−10 M DHEA
(black line) and immunostained for BrdU. Average values are expressed as a
variable of time in vitro, error bars delineate the SEM. A multiple analysis of
variance (MANOVA) was performed to assess the percent variance explained
by the time in culture versus that explained by the presence of DHEA in the
culture medium. Differences between groups for each of these factors were
determined by using one-way ANOVA and Bonferroni’s post hoc test.
Asterisks show signiﬁcant differences between control and DHEA-treated
cultures at each time point. (B) Percent of BrdU immunopositive cells per
total cell number. Values represent the means±SEM of ﬁve independent
platings. Analyses similar to those in A were performed and asterisks show
the signiﬁcance level between control and DHEA-treated cultures at each
time point. (C) Effect of DHEA on growth curve and number of apoptotic cells
in primary culture. Cells were cultured in the presence (black line) or absence
(control, gray line) of DHEA. The total cell number was counted after staining
with Hoechst or wheat-germ agglutinin coupled to a ﬂuorochrome and
expressed as a number of cells/cm2. Apoptosis was assessed with TUNEL
analysis and expressed as a number of apoptotic cells/cm2. Values represent
the means±SEM of ﬁve independent platings.
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demonstrated that DHEA does not sustain survival of the cells
over time.
To determine if the proliferating cells were committing to a
motor neuron fate in culture, we studied the expression of Nkx6.1
(a marker of ventrally committed precursors), Pax6 (a marker of
dorsally committed precursors), and Isl-1/2 (amarker of deﬁnitive
motor neurons). The presence of DHEA in the culture medium
increased the percentage of Nkx6.1+ cells (Figures 4A,B), but not
that of Pax6+ cells (Figure 4C), at the early time points, with
highly signiﬁcant differences between the DHEA-treated and con-
trol cultures at 7–10 h and 18–21 h). We were interested to ﬁnd
that the percentage of Nkx6.1+ cells was increased in DHEA-
treated cells at the same time points when BrdU incorporation was
observed,possibly indicating thatNkx6.1+ cells could incorporate
BrdU. To test this hypothesis, we performed dual immunohisto-
chemistry and found that the percentage of dually labeled cells
for BrdU and Nkx6.1+ cells was signiﬁcantly higher in DHEA-
treated cultures after 7 h (35.3%± 1.5) and 18 h (30.4%± 1.4)
in vitro compared to 21.4%± 1.7 and 20.4%± 0.8 in the control
conditions respectively (Figure 4B), indicating that Nkx6.1+ pop-
ulations represented the majority of cells incorporating BrdU at
these time points. At later time points, the percentage of Nkx6.1+
cells incorporating BrdU was reduced in DHEA-treated culture
and did not differ from control conditions, but they still accounted
for about 20% of the cells incorporating BrdU.We were also inter-
ested that the percentage of Isl-1/2+ cells signiﬁcantly increased in
DHEA-treated culture compared to control cultures with a 8–9 h
delay, as compared to the DHEA-mediated increase observed in
Nkx6.1+ cells. Isl-1/2+ cells represented 30% of the total cell
number after 18 h and 26 h in culture in the presence of DHEA,
as compared to 13 and 15% respectively in control conditions
(Figure 4D), suggesting that the Nkx6.1+ population may have
been further committed into differentiating in motor neurons in
the cultures grown in the presence of DHEA. These experiments
indicate that DHEA promoted proliferation of ventrally com-
mitted precursors and sustained their differentiation into motor
neurons in vitro.
Our results show that BrdU incorporation increased in the pres-
ence of DHEA, even after a long period in culture (the last peak
being observed between 30 and 40 h), but this increase did not
correspond to an increase in the Nkx6.1+ population. Similarly,
although the Isl-1/2+ population was still signiﬁcantly increased
in DHEA-treated cultures after 30–40 h in vitro, the percent of
motor neurons produced in control conditions increased, reduc-
ing the difference between the two culture conditions. Moreover,
the total number of cells decreased in the culture grown in the
presence of DHEA, thus increasing the percentage of motor neu-
rons that survived the culture conditions rather than being actively
differentiated in vitro. These results indicate that cells produced
during the last peak of proliferation are unlikely to be motor neu-
rons. To identify the possible cell types produced in the cultures by
the last peak of proliferation,we examined the expression of mark-
ers of deﬁnitive states of various ventral neurons, including Eng-1
(a marker of committed V1 interneurons) and Chx10 (a marker
FIGURE 4 | Effect of DHEA on the proliferation of committed precursors
in cultures and on the generation of motor neurons in vitro. Cells isolated
from E10.5 mouse neural tube lumbar region were cultured in the presence
(black line) or in the absence (control, gray line) of DHEA for different periods
of time and stained for BrdU and Nkx6.1. (A) Percent of Nkx6.1+ cells. (B)
Percent of dividing Nkx6.1+ cells (dually labeled Nkx6.1 and incorporating
BrdU). (C) Percent of cells expressing Pax6. (D) Percent of Isl-1+ cells. (E)
Percent of other differentiated populations including NeuN+, Eng-1+,
Chx10+, O4+ 30h after seeding. Values represent the means±SEM of ﬁve
independent platings. Statistical analysis was performed as described in
Figure 3. Inset pictures show a representative staining of Nkx6.1, Pax6,
Isl-1/2, and NeuN. Scale above Nkx6.1 inset=10μm.
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of committed V2 interneurons). We also studied the expression
of NeuN (a marker of fully differentiated neurons) and that of
04 (a marker of immature oligodendrocytes) after 30 h in culture
(Figure 4E). DHEA signiﬁcantly increased the neuronal differen-
tiation as assessed by an increased percentage of NeuN+ cells in
the culture but did not signiﬁcantly alter the differentiation of
interneuron populations. Similarly, the population of immature
oligodendrocytes was not signiﬁcantly different in cultures grown
in the presence or in the absence of DHEA. This result indicates
that DHEA may affect not only the proliferation of motor neuron
precursors and the differentiation of motor neurons, but also the
proliferation of other neuronal populations that have yet to be
identiﬁed.
The DHEA-mediated increase in neuronal differentiation requires
the Shh pathway
To determine the mechanism by which DHEA increased Nkx6.1+
cell proliferation andmotor neuron differentiation, we ﬁrst exam-
ined the possibility of DHEA’s acting as an agonist of the NMDA
receptor (Bergeron et al., 1996; Compagnone and Mellon, 1998).
We found no inhibition of DHEA-mediated effects by the NMDA
non-competitive agonist MK801 (not shown), which is consistent
with the lack of expression of theNMDAreceptor at this early stage
(Maric et al., 2000). We then reasoned that the effects observed
with DHEA recapitulated those observed with Shh (Yamada et al.,
1993; Roelink et al., 1995). As Shh can be synthesized and secreted
in our cultures containing induced ﬂoor plate cells, we investi-
gated the Shh signaling pathway to see whether it was involved in
DHEA-mediated effects by using the 5E1 antibody raised against
Shh. 5E1 antibody blocks Shh signal transduction by interfering
with the bindingof Shh toPatched (Fuse et al., 1999;Pepinsky et al.,
2000). We chose to study inhibition of motor neuron differenti-
ation in the cultures at a relatively late stage (35 h after seeding)
in order to obtain enough motor neurons in the control condi-
tions to reliably observe inhibition and yet observe a signiﬁcant
difference between both experimental conditions. The addition
of 5E1 antibody in the control conditions signiﬁcantly blocked
motor neuron differentiation but did not change the fraction of
BrdU-incorporating cells (Figure 5A). When this antibody was
added to cells grown in the presence of DHEA,we observed a total
FIGURE 5 |The effects of DHEA on proliferation and neuronal
differentiation are dependent upon Shh signaling. Cells isolated from
E10.5 mouse neural tube lumbar region were used. (A) Effect of the
addition of the anti-Shh 5E1 blocking antibody (used at 3μg/ml) in control
and DHEA-treated cultures grown for 35 h on BrdU incorporation and Isl-1
expression. The DHEA-mediated increase in BrdU incorporation and Isl-1
expression is signiﬁcant in comparison to the control conditions p ≤0.05).
(B) Effect of addition of the 5E1 blocking antibody in control and
DHEA-treated cultures grown for 21 h on BrdU incorporation and Nkx6.1
expression (The effect of DHEA on BrdU incorporation and Nkx6.1
expression is signiﬁcant in comparison to the control conditions p ≤0.05).
Average data from three independent platings are shown expressed as
percent of control values, error bars are SEM. Statistical analysis was
performed as described in Figure 3.
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inhibition of DHEA-mediated effects, not only on motor neu-
ron differentiation but also on BrdU incorporation (Figure 5A).
These ﬁndings indicate that the proliferating and differentiating
effects of DHEA are dependent on Shh signaling. As all of these
events were possibly initiated earlier during culture by the DHEA-
mediated increase in Nkx6.1+ cell proliferation, we studied dual
expression of Nkx6.1 and BrdU incorporation in cultures grown
in the presence of 5E1 antibody for a shorter period (21 h after
seeding). Addition of 5E1 antibody had no effect on BrdU incor-
poration or on the Nkx6.1 precursor population in the control
cultures (Figure 5B). In the presence of DHEA, however, addition
of the 5E1 antibody reduced the number of BrdU+, Nkx6.1+, and
dually labeled BrdU/Nkx6.1+ cells to the levels seen in the con-
trol cultures, indicating that: (i) the DHEA-mediated increase in
Nkx6.1+ cell proliferation is dependent on Shh signaling pathway;
and (ii) the proliferation of Nkx6.1+ cells precedes motor neuron
differentiation in our culture system and reduction of this phe-
nomenon leads to a signiﬁcant reduction of the DHEA-mediated
differentiation of motor neurons in vitro. The use of an unre-
lated antibody had no signiﬁcant effects on any of these outcomes
(Figure 5B), indicating speciﬁcity of the inhibition observed by
5E1.
These results show a primary effect of DHEA on the prolifera-
tion of the Nkx6.1+ population that translates into an increased
differentiation of motor neurons. This effect is clear during the
ﬁrst 30 h in culture, but then becomes more difﬁcult to follow. In
the late period of culture, increased proliferation does not occur
in the Nkx6.1 population; nonetheless motor neuron differentia-
tion is sustained, although to a lesser extent. This could be due to:
(i) a loss of synchronization in the cell cycle of dividing precur-
sors, making the proliferation and differentiation phases overlap;
(ii) an increased survival of motor neurons in the presence of
DHEA (even though the rate of apoptosis and the total cell num-
ber abruptly drop in the late cultures grown in the presence of
DHEA); or (iii) a possible direct effect of DHEA on the induction
of motor neurons superimposed on the proliferative effects of
DHEA. Because the primary spinal cord precursor culture model
does not allow us to discriminate between possible proliferative
and inductive effects of DHEA in spinal cord ventral progenitor
we have studied this question in more details using other models.
EFFECT OF DHEA IN MOTOR NEURON SPECIFICATION DETERMINED
WITH INTERMEDIATE NEURAL PLATE EXPLANTS
In vivo, induction of class I and class II protein expression in
uncommitted precursors shortly precedes the proliferation of ven-
tral progenitors. Precursors committed to become motor neurons
express Olig-2 and exit the cell cycle (Novitch et al., 2001). The
increase in the proportion of mature motor neurons (Isl-1+)
in our primary cultures with DHEA may derive from the prior
increase in the proliferation of the pool of ventral precursors,
but alternatively it may possibly derive from a direct effect of
DHEA on the induction of the expression of homeoprotein pro-
teins specifying motor neuron development among these cells
(Nkx6.1, Olig-2, and then Isl-1/2). To test this possibility, we iso-
lated intermediate neural plate explants from E10mouse embryos
and cultured them ﬁrst for 12 h in a serum-free medium to wash
any residual induction factors, and then for an additional 24 h
in fresh serum-free medium containing either no induction sig-
nal, or DHEA (10−10 M), or different concentrations (2, 7, and
20 nM) of Shh alone or with DHEA (10−10 M). We monitored
the expression of class I homeoprotein Pax7 (Figures 6A,C), class
II homeoprotein Nkx6.1, motor neuron progenitor state marker
Olig-2, and deﬁnite post-mitotic motor neuron marker Isl-1/2.
When grown alone, cells in explants expressed low levels of class
II protein Nkx6.1 and high levels of class I protein Pax7. Very
few cells or none expressed Olig-2 or Isl-1/2. In the presence of
DHEA, expression of class I protein Pax7 was reduced whereas
that of class II protein Nkx6.1 was increased to a level comparable
to that of explants grown in the presence of 2 nM Shh. DHEA also
induced expression of Olig-2 and Isl-1/2 (Figures 6A,C). Thus
DHEA exerted a repressive action of class I protein expression
and an activating action of class II protein expression in vitro,
mimicking the action of Shh signaling. In this context, the num-
ber of class II protein expressing progenitors was increased to a
higher extent than that of motor neuron progenitors and deﬁni-
tive motor neurons, suggesting that the extinction of class I and
the increase in class II proteins induced by DHEA may have trig-
gered the cascade of transcriptional repressors that directs motor
neuron generation (Novitch et al., 2001, 2003; Shirasaki and Pfaff,
2002). The addition of DHEA-induced a potentiation of the effects
of Shh alone when present at 2 nM in the cultures (Figure 6C).
DHEA potentiated Shh effects at 7 nM on motor neuron precur-
sor induction (p ≤ 0.0001) but not at 20 nM when Shh activity
peaks and cannot be furthered by DHEA neither on induction
of motor neuron precursors, deﬁnite motor neuron nor on the
repression of class I proteins (Figure 6C). The effect of the com-
bination of both signals was not synergic but rather additive and
saturable, suggesting a mechanism involving a saturating mem-
brane process. To study this issue more closely, and as we had
previously observed that the effects mediated by DHEA were Shh-
dependent in our primary culture model, we examined whether
the DHEA-mediated induction of class II protein expression, the
generation of motor neuron progenitors, and the generation of
deﬁnitivemotor neurons are dependent on the Shh signaling path-
way by using the blocking antibody 5E1 and the Shh antagonist
cyclopamine. In the presence of either 5E1 or cyclopamine, the
induction of Nkx6.1 (not shown), Olig-2, and Isl-1/2 expression
by DHEA was abolished (Figures 6B,C), suggesting that DHEA
mediates its effects through a mechanism dependent on an intact
Shh signaling pathway.
To explore whether this effect was also operative in the DHEA-
mediated repression of class I protein expression, we studied
the expression of Pax7 in the explants treated with DHEA in
the presence of 5E1 or cyclopamine. Neither cyclopamine nor
5E1 blocked the repression of Pax7 expression in DHEA-treated
explants (Figure 6B), indicating that DHEA mediates the repres-
sion of Pax7, and possibly that of other class I proteins, in amanner
independent of Shh signaling. Similarly, the addition of DHEA to
Shh-treated explants did not increase the repression of Pax7 above
the level observed in explants treated with Shh alone.
It appears, from these ﬁndings, that DHEA can induce expres-
sion of class II proteins and reduce the expression of class I
proteins,mimicking Shh signaling. However, the DHEA-mediated
induction of class I protein is dependent on the Shh pathway,
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FIGURE 6 |The effects of DHEA on induction of class I and II
homeodomain protein, a motor neuron precursor marker, and a
definitive motor neuron precursor in intermediate neural plate
explants. Intermediate neural plates isolated from E10 thoracic mouse
neural tubes were used. (A) Photomicrograph representative of explants
cultured in control conditions (without inductive factors) in the presence of
2 nM of Shh, in the presence of 10−10 M DHEA, or in the presence of Shh
2 nM and 10−10 M DHEA.We studied expression of Nkx6.1, Pax7, Olig-2, and
Isl-1/2. (B) Expression of Pax7, Olig-2, and Isl-1/2 in the presence of DHEA
alone or with 5E1 (3μg/ml), a blocking antibody against Shh, or
cyclopamine, an antagonist of Shh signaling. (C) Quantiﬁcation of (A) is
shown in the table. Data are the number of immunopositive cells per
100μm2 ±SEM. Quantiﬁcation of (B) and of all the other conditions tested
is shown in the different graphs representing the number of
immunopositive cells per 100μm2 ±SEM for Pax7, Olig-2, and Isl-1/2
respectively. A MANOVA analysis was performed to determine the inﬂuence
of the dose of Shh used and that of the composition of the culture medium.
Differences between the different medium compositions at every single
dose of Shh were determined by ANOVA and Bonferroni post hoc analysis.
*=p<0.05, **=p<0.001, ***=p<0.0001.
whereas the DHEA-mediated repression of class I protein expres-
sion occurs independently from Shh.We have also shown that the
DHEA-mediated induction of class II protein expression can trig-
ger expression of motor neuron progenitor protein markers and
expression of deﬁnitive motor neurons in vitro.
EFFECT OF DHEA ON CELL PROLIFERATION DETERMINED WITH WHOLE
SPINAL CORD EXPLANTS
To study the effects of DHEA in the context of the whole spinal
cord, we used spinal cord explant cultures isolated from the
lumbo-sacral region of E11 mouse embryos. At this A/P level and
stage, DHEA is endogenously produced at very low levels (see
Figure 2D). Thus the effects observed were due to the exogenous
addition of DHEA in the culture medium for 24 h. We measured
BrdU incorporation in explants grown in the presence or absence
of DHEA (Figure 7). In the control condition, a low but consis-
tent level of BrdU incorporation was observed (Figure 7A). In
this in vitro model, in which the SVZ is exposed, BrdU incorpora-
tion was increased in the presence of DHEA in 80%of the explants
studied (Figure 7A). Increased proliferationwasmostly seen in the
SVZ region surrounding the ﬂoor plate, and it gradually decreased
from the ventral to the dorsal region of the ﬂattened spinal cord
(Figures 7B,C). In the dorsal spinal cord, no signiﬁcant differences
were observed between control andDHEAexplants (Figure 7B,C).
Only half of the explants grown in the presence of DHEA showed a
low number of BrdU incorporated cells that extended in the dorsal
domain. These observations strongly suggested that the prolifera-
tive response to DHEA depended on the gradient of Shh along the
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FIGURE 7 | Effect of DHEA on cell proliferation in spinal cord explants.
(A) BrdU immunostaining of E11.5 lumbar spinal cord explants cultured in the
absence (Control) or presence of DHEA or its derivative ﬂuasterone, with or
without the 5E1 anti-Shh antibody. Bar=0.5mm. (B) Layout of the spinal cord
explant in the collagen matrix. The different regions in which BrdU
incorporation was quantiﬁed are shown. (C) Quantiﬁcation of BrdU
incorporation in the whole explant (Total), central part (∼100μm around the
ﬂoor plate), and ventral and dorsal domains. Results are expressed as a
number of immunopositive BrdUcells/mm2 to correct for different sizes of
explants. (D) Photomicrograph of whole spinal cord explants immunostained
for BrdU (red) and Olig-2 (Green) showing the effect of DHEA on the
expansion of the ventrally committed precursor domain and the dorsal shift of
the Olig-2+ domain. These effects are antagonized in the presence of 5E1,
which also abolished the Shh-mediated induction of Olig-2 expression.
(fp=ﬂoor plate, bar=100μm). Quantiﬁcation of the distance and width of
the Olig-2+ motor neuron precursor domain is shown in each experimental
condition. Quantiﬁcation of the number of the BrdU-incorporating cells in the
ventral committed precursor domain is shown. Values represent the
means±SEM of three independent platings. One-way ANOVA analysis was
performed to assess signiﬁcance of the treatment. Signiﬁcant differences
between groups were determined with Bonferroni post hoc analysis.
*=p<0.05, **=p<0.001, ***=p<0.0001.
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ventro-dorsal axis of the cord. To conﬁrm this hypothesis, we used
the 5E1 antibody and observed a complete abolition of DHEA-
induced proliferation (Figures 7A–C). In all explants treated with
the 5E1 antibody, the ﬂoor plate appeared to be uniformly labeled
(Figure 7A). One possible explanation for this result is the detec-
tion of the monoclonal 5E1 antibody attached to the surface of
ﬂoor plate cells. Because 5E1 and BrdU antibodies are both mon-
oclonal antibodies, the secondary antibody used to detect BrdU
in these explants will also bind to the 5E1 antibody when present.
These results show that, in the presence of endogenous secretion
of Shh by ﬂoor plate cells, DHEA-induced proliferation of neural
precursors of the SVZ. To assess that this effect was direct, and
not due to the possible metabolism of DHEA in other steroids, we
used a non-androgenic ﬂuorinated analog of DHEA, ﬂuasterone
(Schwartz and Pashko, 1995). As shown in Figure 7, the same Shh-
dependent increase of BrdU incorporation in the ventral SVZ was
seen with ﬂuasterone as with DHEA. The effects observed are thus
directly due to the presence of DHEA.
We then determined whether the ventro-dorsal patterning of
the explants was modiﬁed under these conditions by studying
Olig-2 expression. In the presence of DHEA, we observed an
increased proliferation of the ventrally committed neural precur-
sors, which resulted in a dorsal shift of the Olig-2+ motor neuron
precursor domain (Figure 7D). Although some proliferative cells
are observed in the olig-2+ domain, cells expressing Olig-2 do not
incorporate BrdU, consistent with their post-mitotic state. DHEA
also increased the level of Olig-2 expression and the size of the
Olig-2 domain, indicating an increased induction of this pro-
tein expression in a larger number of motor neuron precursors
(Figure 7D). These results show that physiological levels of DHEA
allowed for a sustained proliferation of ventrally committed pre-
cursors in spinal cord explants. As a result of the expansion of
the ventral progenitors, the domain of the motor neuron precur-
sors shifts dorsally. Increased proliferation of ventrally committed
precursors (possibly includingNkx6.1+precursors)may also con-
tribute to a larger pool of – motor neuron precursors observed in
explants cultured in thepresenceof DHEA.DHEA-mediatedBrdU
incorporation andOlig-2 expressionwere abolished by adding 5E1
antibody to the culture medium, demonstrating the dependence
of the effects observed on Shh signaling (Figure 7D).
DISCUSSION
This study addresses how DHEA, a neurosteroid produced in the
developing neural tube, may potentiate the biological response
of ventral precursors to Shh. The results establish that DHEA is
biosynthesized in the developing ventral neural tube at the time
of neurogenesis and cell fate determination. In in vitro models,
DHEAmodulated the induction of expression of Nkx6.1, a class II
homeodomain protein, as well as expression of the homeodomain
proteins Olig-2, a speciﬁc motor neuron precursor marker, and
Isl-1/2, a deﬁnitive motor neuron marker. Moreover, DHEA pro-
moted proliferation of ventral neuronal progenitors committed
into the derepression cascade leading to the generation of motor
neurons. Both of these biological actions of DHEA are depen-
dent on Shh. These results support the hypothesis that DHEA
biosynthesis participates in the Shh-mediated induction of ven-
tral neuronal populations and controls the proliferative response
of neuronal progenitors to Shh in themid-gestation ventral neural
tube in vivo. We found, in addition, that DHEA represses expres-
sion of Pax7, a class I homeodomain protein, in intermediate
neural plate explants in a manner independent from Shh. This
observation remains to be further documented.
DHEA BIOSYNTHESIS IN THE DEVELOPING NEURAL TUBE
In this study, P450c17, an enzyme crucial for the biosynthesis of
DHEA, was expressed in the neural tube in a regulated spatial
and temporal pattern. Expression of P450c17 in the developing
neural tube was ﬁrst seen at E10 in the differentiated ﬁeld of the
neural tube in the cervical region. It then extended to all A/P levels
at E13 and became localized in subsets of motor neuron pools.
These results establish that expression of P450c17 correlates with
its activity in the developing neural tube. Moreover, this activity
was regulated along the A/P axis of the neural tube. As P450c17
expression remains detectable several days after the biosynthesis
of DHEA stops, it appears that the regulation of DHEA biosynthe-
sis does not rely solely on transcriptional regulation of P450c17.
Future studiesmust determine themechanism regulating the tem-
poral and regional activity of P450c17 among (i) the availability of
speciﬁc cofactors, (ii) competition for its rate-limiting substrate,
or (iii) further conversion of DHEA into androgens. The period
of time during which DHEA is biosynthesized in the developing
neural tube corresponds to the period during which neurogen-
esis occurs. Neural progenitors emerging from the SVZ remain
highly proliferative while inductive signals – such as withdrawal
of FGF, retinoic acid, and Shh secretion – dictate cell fate deci-
sions through a transcriptional derepression strategy (Muhr et al.,
1999). As the identity of repressor cascades in the ventral spinal
cord have been largely deﬁned for pathways of motor neuron and
interneuron generation (Briscoe et al., 2001; Muhr et al., 2001),
we focused on determining the biological action of DHEA in the
ventral neural tube by using in vitro models recapitulating ventral
neuron generation.
INDUCTION AND PROLIFERATION: A COOPERATIVE MECHANISM TO
CONTROL THE MN POOL
Motor neurons and ventral interneurons are generated through
a pathway that involves secretion of Shh from the notochord and
ﬂoor plate (Patten and Placzek, 2000). Shh has diverse functions in
the developing neural tube through a common signaling pathway
(reviewed in Ingham and McMahon, 2001; Marti and Bovolenta,
2002). Shh signaling is critical for ventral neuronal differentiation.
Dysfunction in the Shh signaling pathway in mice is associated
with defects in ventral neural patterning (Chiang et al., 1996). In
humans, it produces several pathologic conditions, such as holo-
prosencephaly, cyclopia, and impaired development of the neural
tube and limbs, as well as various types of skin and CNS cancers,
including medulloblastoma (reviewed in McMahon et al., 2003;
Roessler andMuenke, 2003). In the neural tube, Shh has a primor-
dial role in dictating cell fate in ventral precursors (Jessell, 2000;
Briscoe et al., 2001; Lee and Pfaff, 2001). Shh is necessary and suf-
ﬁcient to specify ventral neuronal populations, as demonstrated
through genetic ablation of its expression in the mouse (Chi-
ang et al., 1996) and by using chick embryos electroporated with
mutated forms of Shh responsible for human holoprosencephaly
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(Schell-Apacik et al., 2003). An elegant demonstration of dose-
dependent gene activity in response to various concentrations of
puriﬁed Shhhas led to the interpretation that Shh controls ventral-
ization of the neural tube through graded signals (Roelink et al.,
1995; Ericson et al., 1997). A study of the mouse retina suggested
Shh regulation in cell proliferation (Jensen and Wallace, 1997),
and several other studies have clearly implicated Shh signaling
in the developing mouse cerebellum, where the development of
granule-cell precursors depends on the expression of Shh by Purk-
inje cells (Dahmane et al., 1997; Wallace, 1999; Weshcelard-Reya
and Scott, 1999). Proliferative effects of Shh in the spinal cord
have been shown both in vitro and in vivo (Kalyani et al., 1998;
Rowitch et al., 1999). Rowitch et al. (1999) produced a trans-
genic mouse in which Shh was ectopically expressed in the dorsal
neural tube and persisted beyond the time when normal neuro-
genesis occurred. In that model, the ectopic expression of Shh
produced an increased proliferation of precursor cells only when
induced in the embryo early, at a timewhenneurogenesis normally
occurs. Ectopic expression of Shh at a later stage did not produce
a proliferative response of precursors still present within its sig-
naling range. It appears, then, that environmental cues participate
in the modulation of the type of response of neural precursors to
Shh signaling. Our experiments indicate that DHEA is capable of
recapitulating Shh signaling by inducing Nkx6.1, Olig-2, and Isl-
1/2 expression in E10 intermediate neural plate explants. While
controlling cell fate decisions in neural precursors in a manner
dependent on Shh, DHEA also controls proliferation of ventral
neuronal-precursors both in isolated primary cultures and in E11
whole spinal cord explants. Evidence that the effects mediated by
DHEA are abolished by antagonists of the Shh signaling pathway
indicate that DHEA mediates its effects in a manner dependent
on the Shh signaling pathway. Based on those ﬁndings, we pro-
pose that the time during which DHEA is biosynthesized in vivo
may represent a temporal window of opportunity for ventral
neuronal-precursor to proliferate in response to Shh, and its clos-
ing thus controls the number of pre-committed neurons. During
that period, DHEA may also enhance the bioactivity of Shh in
specifying the same ventral precursors that proliferate in response
to DHEA and Shh into ventral neuronal subtypes, including those
of motor neurons. These observations must be conﬁrmed in an
in vivo model.
An intriguing observation is the fact that DHEA repressed Pax7
expression in a manner independent of Shh signaling. This obser-
vation established in intermediate neural plate explants needs to
be conﬁrmed in models more closely related to the physiology of
the developing dorsal neural tube. Nonetheless, if our observation
was conﬁrmed in models allowing the study of dorsal patterning
under normal BMP signaling, DHEA being produced by commis-
sural neurons, could participate in the control of Pax7 expression
dorsally. In vivo, Pax7 expression is seen in the dorsal cord at the
time when DHEA biosynthesis occurs, thus making the repressing
effects of DHEA possible. But because in vivo inhibition of Shh
biogenesis or signaling is enough to derepress expression of Pax7
in the ventral neural tube (Chiang et al., 1996; Incardona et al.,
1998), it is unlikely that DHEA biosynthesis may be sufﬁcient to
repress Pax7 expression alone. This issuemust be studied in greater
details.
MECHANISMS OF ACTION
DHEA is a pleiotropic molecule that has several potential mecha-
nisms of action (review in Compagnone andMellon, 2000). In the
developing embryo, it is mostly seen as acting either (i) as a weak
NMDA agonist (Compagnone and Mellon, 1998) and GABAA
antagonist (Majewska, 1995) or (ii) as a precursor of androgens,
indirectly acting through the local biosynthesis of androstene-
dione, testosterone, or estradiol after aromatization. Evidence of
a direct action of DHEA lies in our conﬁrmatory results with
ﬂuasterone, which – as ﬂuasterone cannot be metabolized into
androgens or estrogens – eliminate the possibility that the effects
observed could be due to the metabolism of DHEA into andro-
gens or estrogens. The possibility that DHEA-mediated its effects
by inducingNMDA receptor activation was also excluded, and our
results are consistent with the fact that the units forming a func-
tional NMDA receptor are not expressed at this early embryonic
stage (Maric et al., 2000).
Our ﬁndings indicate that DHEA mediates motor neuron
induction and ventral neuronal-precursor proliferation through a
signaling pathway dependent on Shh.We can speculate thatDHEA
could interact with the Shh signaling pathway at several levels. Five
possibilities need to be further analyzed: (1) DHEA may increase
Shh expression in neural cells (2) DHEA could function as an
agonist of the Shh pathway (3) DHEA may function in parallel
and synergistically to Shh signaling (4) DHEA may function as
an antagonist of BMP signaling (5) DHEA may modulate Shh
range and activity gradient dependent on its lipid modiﬁcation.
Shh is dually lipid-modiﬁed, with palmitic acid at its N-terminus
and cholesterol at its C-terminus (Mann and Beachy, 2004). Even
though DHEA is present in vivo at concentrations in the femto-
to pico-molar range – far below those needed for the interac-
tion between cholesterol and Shh to occur (Porter et al., 1996),
the last hypothesis is appealing because cholesterol modulation of
Shh activity has been proposed to explain the differential effect
of Shh in patterning the spinal cord versus telencephalon. Mice
in which Shh lacks the cholesterol moiety show defect in ventral
neuron speciﬁcation and ganglionic eminence development in the
telencephalon, while a full spectrum of the ventral cell type is
observed in the spinal cord (Huang et al., 2007). DHEA is pro-
duced in an antero/posterior gradient in the spinal cord at the
time of neural precursor proliferation. Therefore, it may substi-
tute for cholesterol and interact with Shh in the spinal cord at the
time of ventral precursor proliferation and speciﬁcation.However,
P450c17 expression is posterior to ventral neural precursors pro-
liferation and speciﬁcation by Shh signaling in the telencephalon
(Compagnone and Mellon, 1998). These hypotheses need to be
tested in other in vitro and in vivo models and are currently under
investigation. In vivo models will require conditional knock-out of
P450c17 enzyme since P450c17 knock-out mice have been devel-
oped and are embryonic lethal prior to gastrulation (Bair and
Mellon, 2004).
ACKNOWLEDGMENTS
For the gift of reagents, we thank Dr. Walter Miller (Univer-
sity of California, San Francisco, CA, USA) for the anti-human
P450c17 antibody, Dr. Mike German (University of California,
San Francisco, CA,USA) for the anti-Nkx6.1 antibody,Dr. Samuel
www.frontiersin.org February 2012 | Volume 3 | Article 16 | 13
Galdo et al. DHEA and ventral spinal cord precursors
Pfaff (The Salk Institute, La Jolla, CA, USA) for the anti-Isl2,
Lim3, HB9, and Chx10 antibodies, Dr. Thomas Jessell and Dr.
Bennett Novitch (Columbia University, NY, USA) for Olig-2 anti-
body, Dr. Richard Auchus (UT Southwestern Medical Center,
Dallas,TX,USA) forP450c17 enzymatic activity radiolabeled stan-
dard, derived from P450c17 over-expressing yeast, and Dr. Arthur
Schwartz (Temple University, Philadelphia, PA, USA) for ﬂuas-
terone. The anti-Shh (5E1), anti-Isl-1 (40.2D6), and anti-Lim1/2
(4F2) antibodies, developed by Dr. Thomas Jessell, the anti-Pax6
and the anti-Pax7 antibodies, developed byDr. Atsushi Kawakami,
were obtained from the Developmental Studies Hybridoma Bank
(DSHB) developed under the auspices of the NICHD and main-
tained by The University of Iowa, Department of Biological
Sciences, Iowa City, IA 52242, USA. We also thank Drs. Marc
Tessier-Lavigne, John Rubenstein, and Oscar Marin, for fruitful
discussions along the course of the redaction of this manuscript.
This workwas supported by a grant from theUniversity of Califor-
nia, Research Evaluation and Allocation Committee, a grant from
the Muscular Dystrophy Association and the generous gift from
the Charitable Columbia Foundation to NAC. CF was supported
by a fellowship from the Association for the Research on Cancer
(ARC) and by grant NIH-NS41998 to NAC.
REFERENCES
Auchus,R. J.,Geller,D.H.,Lee,T.C., and
Miller, W. L. (1998). The regulation
of human P450c17 activity: rela-
tionship to premature adrenarche,
insulin resistance and the polycystic
ovary syndrome. Trends Endocrinol.
Metab. 9, 47–50.
Bair, S. R., and Mellon, S. H. (2004).
Deletion of the mouse P450c17
gene causes early embryonic lethal-
ity. Mol. Cell. Biol. 24, 5383–5390.
Barzi, M., Berenguer, J., Menendez, A.,
Alvarez-Rodriguez, R., and Pons, S.
(2010). Sonic hedgehog-mediated
proloferation reguires the locaiza-
tionof PKA to the ciliumbase. J. Cell.
Sci. 123(Pt 1), 62–69.
Bergeron, R., de Montigny, C., and
Debonnel,G. (1996). Potentiation of
neuronal NMDA response induced
by dehydroepiandrosterone and its
suppression by progesterone: effects
mediated via sigma receptors. J.Neu-
rosci. 16, 1193–1202.
Briscoe, J., Chen, Y., Jessell, T. M.,
and Struhl, G. (2001). A hedgehog-
insensitive form of patched provides
evidence for direct long-range mor-
phogen activity of sonic hedgehog
in the neural tube. Mol. Cell 7,
1279–1291.
Briscoe, J., Pierani, A., Jessell, T. M., and
Ericson, J. (2000). A homeodomain
protein code speciﬁes progenitor cell
identity andneuronal fate in the ven-
tral neural tube. Cell 101, 435–445.
Brito, J., Tannahill, D., and Keynes, R.
(2002). A critical role for sonic hege-
hog signaling in the early expan-
sion of the developing brain. Nat.
Neurosci. 5, 103–110.
Chiang,C.,Litingtung,Y.,Lee,E.,Young,
K. E.,Corden, J. L.,Westphal,H., and
Beachy, P. A. (1996). Cyclopia and
defective axial patterning in mice
lacking sonic hedgehog gene func-
tion. Nature 383, 407–413.
Colamarino, S. A., and Tessier-Lavigne,
M. (1995). The axonal chemoattrac-
tant netrin-1 is also a chemorepel-
lent for trochlear motor axons. Cell
81, 621–629.
Compagnone, N. A., Bulfone, A.,
Rubenstein, J. L., and Mellon, S.
H. (1995a). Steroidogenic enzyme
P450c17 is expressed in the embry-
onic central nervous system.
Endocrinology 136, 5212–5223.
Compagnone, N. A., Bulfone, A.,
Rubenstein, J. L., and Mellon, S. H.
(1995b). Expression of the steroido-
genic enzyme P450scc in the cen-
tral and peripheral nervous sys-
tems during rodent embryogenesis.
Endocrinology 136, 2689–2696.
Compagnone, N. A., and Mellon, S.
H. (1998). Dehydroepiandros-
terone: a potential signalling
molecule for neocortical orga-
nization during development.
Proc. Natl. Acad. Sci. U.S.A. 95,
4678–4683.
Compagnone, N. A., and Mellon, S. H.
(2000). Neurosteroids: biosynthesis
and function of these novel neuro-
modulators. Front. Neuroendocrinol.
21, 1–60.
Dahmane, N., lee, J., robins heller, P.,
and ruiz-i-altaba, A. (1997). Activa-
tion of the transcirption factor Gli1
and the sonic hedgehog signaling
pathway in skin tumors. Nature 389,
876–881.
Ericson, J., Briscoe, J., Rashbass, P., van
Heyningen, V., and Jessell, T. M.
(1997). Graded sonic hedgehog sig-
naling and the speciﬁcation of cell
fate in the ventral neural tube. Cold
Spring Harb. Symp. Quant. Biol. 62,
451–466.
Ericson, J., Morton, S., Kawakami, A.,
Roelink,H., and Jessell, T.M. (1996).
Two critical periods of sonic hedge-
hog signaling required for the spec-
iﬁcation of motor neuron identity.
Cell 87, 661–673.
Fuse, N., Maiti, T., Wang, B., Porter,
J. A., Hall, T. M., Leahy, D. J., and
Beachy, P. A. (1999). Sonic hedgehog
protein signals not as a hydrolytic
enzyme but as an apparent ligand for
patched. Proc. Natl. Acad. Sci. U.S.A.
96, 10992–10999.
Hagedorn, L., Floris, J., Suter, U., and
Sommer, L. (2000). Autonomic neu-
rogenesis and apoptosis are alterna-
tive fates of progenitor cell commu-
nities induced byTGFbeta.Dev. Biol.
228, 57–72.
Huang, X., Litingtung, Y., and Chi-
ang, C. (2007), Region-speciﬁc
requirement for cholesterol mod-
iﬁcation of sonic hedgehog in
patterning the telencephalon and
spinal cord. Development 134,
2095–2105.
Incardona, J. P., Gafﬁeld, W., Kapur,
R. P., and Roelink, H. (1998).
The teratogenic vertrum alkaloid
cyclopamine inhibits sonic hedge-
hog signal transduction. Develop-
ment 125, 3553–3562.
Ingham, P. W., and McMahon, A.
P. (2001). Hedgehog signaling in
animal development: paradigms
and principles. Genes Dev. 15,
3059–3087.
Jensen, A. M., andWallace,V. A. (1997).
Expression of sonic hedgehog and its
putative role as a precursor cellmito-
gen in the developing mouse retina.
Development 124, 363–371.
Jessell, T.M. (2000). Neuronal speciﬁca-
tion in the spinal cord: inductive sig-
nals and transcriptional codes. Nat.
Rev. Genet. 1, 20–29.
Kalyani, A. J., Piper, D., Mujtaba, T.,
Lucero, M. T., and Rao, M. S.
(1998). Spinal cord neuronal pre-
cursors generate multiple neuronal
phenotypes in culture. J. Neurosci.
18, 7856–7868.
Lee, S. K., and Pfaff, S. L. (2001).
transcriptional networks regulating
neuronal identity in the develop-
ing spinal cord. Nat. Neurosci. 4,
1183–1191.
Litingtung, Y., and Chiang, C. (2000).
Speciﬁcation of ventral neuron types
is mediated by an antagonistic inter-
action between Shh and Gli3. Nat.
Neurosci. 3, 979–985.
Majewska, M. D. (1995). Neuronal
actions of dehydroepiandrosterone.
Possible roles in brain development,
aging, memory, and affect. Ann. N.
Y. Acad. Sci. 774, 111–120.
Mann, R. K., and Beachy, P. A. (2004).
Novel lipidmodiﬁcations of secreted
protein signals. Annu. Rev. Biochem.
73, 891–923.
Maric, D., Liu, Q., Grant, G., Andreadis,
J., Hu, Q., Chang, Y., Barker, J.,
Joseph, J., Stenger, D., and Ma, W.
(2000). Functional ionotropic gluta-
mate receptors emerge during ter-
minal cell division and early neu-
ronal differentiation of rat neuroep-
ithelial cells. J. Neurosci. Res. 61,
652–662.
Marti, E., and Bovolenta, P. (2002).
Sonic hedgehog in CNS develop-
ment: one signal, multiple output.
Trends Neurosci. 25, 89–96.
McMahon, A. P., Ingham, P. W., and
Tabin, C. J. (2003). Developmen-
tal roles and clinical signiﬁcance of
hedgehog signaling. Curr. Top. Dev.
Biol. 53, 1–114.
Muhr, J., Andersson, E., Persson, M.,
Jessell, T., and Ericson, J. (2001).
Groucho-mediated transcriptional
repression establishes progenitor cell
pattern and neuronal fate in the ven-
tral neural tube. Cell 104, 861–873.
Muhr, J., Graziano, E., Wilson, S.,
Jessell, T. M., and Edlund, T.
(1999). Convergent inductive sig-
nals specify midbrain, hindbrain,
and spinal cord identity in gastrula
stage chick embryos. Neuron 23,
689–702.
Nornes, H. O., and Carry, M. (1978).
Neurogenesis in spinal cord of
mouse: an autoradiographic analy-
sis. Brain Res. 159, 1–6.
Novitch,B.,Wichterle,H., Jessell,T., and
Sockanathan, S. (2003). A require-
ment for retinoic acid-mediated
transcriptional activation in ventral
neural patterning andmotor neuron
speciﬁcation. Neuron 40, 81–95.
Novitch, B. G., Chen, A. I., and Jessell,
T. M. (2001). Coordinate regulation
of motor neuron subtype identity
and pan-neuronal properties by the
bHLH repressor Olig2. Neuron 31,
773–789.
Patten, I., and Placzek, M. (2000). The
role of sonic hedgehog inneural tube
patterning. Cell. Mol. Life Sci. 57,
1695–1708.
Pepinsky, R. B., Rayhorn, P., Day, E. S.,
Dergay, A., Williams, K. P., Galdes,
A., Taylor, F. R., Boriack-Sjodin, P.
A., and Garber, E. A. (2000). Map-
ping sonic hedgehog-receptor inter-
actions by steric interference. J. Biol.
Chem. 275, 10995–11001.
Frontiers in Endocrinology | Neuroendocrine Science February 2012 | Volume 3 | Article 16 | 14
Galdo et al. DHEA and ventral spinal cord precursors
Porter, J. A., Young, K. E., and Beachy,
P. A. (1996). Cholesterol modiﬁca-
tion of hedgehog signaling proteins
in animal development. Science 274,
255–259. [Erratum in: Science 274,
1597].
Roelink, H., Porter, J. A., Chiang, C.,
Tanabe, Y., Chang, D. T., Beachy, P.
A., and Jessell, T. M. (1995). Floor
plate and motor neuron induction
by different concentrations of the
amino-terminal cleavage product of
sonic hedgehog autoproteolysis. Cell
81, 445–455.
Roessler, E., and Muenke, M. (2003).
How a hedgehog might see holo-
prosencephaly.Hum. Mol. Genet. 12,
R15–R25.
Rowitch, D. H., St. Jacques, B., Lee,
S. M. K., Flax, J. D., Snyder, E.
Y., and McMahon, A. P. (1999).
Sonic hedgehog regulates prolifera-
tion and inhibits differentiation of
CNS precursor cells. J. Neurosci. 19,
8954–8965.
Rubenstein, J. L., and Beachy, P. A.
(1998). Patterning of the embryonic
forebrain. Curr. Opin. Neurobiol. 8,
18–26.
Ruiz i Altaba, A., Palma, V., and Dah-
mane, N. (2002). Hedgehog-Gli sig-
nalling and the growth of the brain.
Nat. Rev. Neurosci. 31, 24–33.
Schell-Apacik, C., Rivero, M., Knepper,
J. L., Roessler, E., Muenke, M., and
Ming, J. E. (2003). Sonic hedgehog
mutations causing humanholopros-
encephaly impair neural patterning
activity. Hum. Genet. 113, 170–177.
Schwartz, A., and Pashko, L.
(1995). Cancer prevention with
dehydroepiandrosterone and non-
androgenic structural analogs. J.
Cell. Biochem. Suppl. 22, 210–217.
Shirasaki, R., and Pfaff, S. (2002). Tran-
scriptional codes and the control of
neuronal identity. Annu. Rev. Neu-
rosci. 25, 251–281.
Wallace, V. A. (1999). Purkinje-cell-
derived sonic hedgehog regulates
granule neuron precursor cell pro-
liferation in the developing mouse
cerebellum. Curr. Biol. 9, 445–448.
Weshcelard-Reya, R. J., and Scott, M.
P. (1999). Control of neuronal
precursor proliferation in the cere-
bellum by sonic hedgehog. Neuron
22, 103–114.
Wetmore, C. (2003). Sonic hedge-
hog in normal and neoplastic
proliferation: insight gained from
human tumors and animal mod-
els. Curr. Opin. Genet. Dev. 13,
34–42.
Yamada, T., Pfaff, S. L., Edlund, T., and
Jessell, T. M. (1993). Control of cell
pattern in the neural tube: motor
neuron induction by diffusible fac-
tors from notochord and ﬂoor plate.
Cell 73, 673–686.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 19 July 2011; paper pending
published: 23 August 2011; accepted: 19
January 2012; published online: 07 Feb-
ruary 2012.
Citation: Galdo M, Gregonis J, Fiore
CS and Compagnone NA (2012) Dehy-
droepiandrosterone biosynthesis, role,
and mechanism of action in the devel-
oping neural tube. Front. Endocrin. 3:16.
doi: 10.3389/fendo.2012.00016
This article was submitted to Frontiers
in Neuroendocrine Science, a specialty of
Frontiers in Endocrinology.
Copyright © 2012 Galdo, Gregonis, Fiore
and Compagnone. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
Non Commercial License, which per-
mits non-commercial use, distribution,
and reproduction in other forums, pro-
vided the original authors and source are
credited.
www.frontiersin.org February 2012 | Volume 3 | Article 16 | 15
